Skip to main content

Table 5 Mixed model analysis estimates of fixed effects and covariance

From: Development of a novel, sensitive translational immunoassay to detect plasma glial fibrillary acidic protein (GFAP) after murine traumatic brain injury

Plasma pool Mean concentration (pg/mL) Group variation Intra-assay variation Inter-assay variation
SE (pg/mL) Variance (pg/mL) SD (pg/mL) SE (pg/mL) %CV Variance (pg/mL) SD (pg/mL) SE (pg/mL) %CV
All (model 1A) 1720.0 93.5 3484.7 59.0 26.4 3.4 17,763.2 133.3 59.6 7.7
Low (model 2B) 43.4 4.0 2.0 0.9 4.6 3.5 1.9 0.8 4.3
Intermediate (model 3C) 136.6 23.5 4.8 2.2 3.5 24.2 4.9 2.2 3.6
High (model 4D) 4979.9 0.0 0.0 0.0 0.0 70,844.3 266.2 119.0 5.3
  1. AAll groups: plasma pool = fixed effect, technical replicate = random effect nested in assay date, assay date = random effect. BLow plasma pool: technical replicate = random effect nested in assay date, assay date = random effect. CIntermediate plasma pool: technical replicate = random effect nested in assay date, assay date = random effect. DHigh plasma pool: technical replicate = random effect nested in assay date, assay date = random effect. SD for intra-assay and inter-assay variation were calculated as follows: SD= √variance). SE for intra-assay and inter-assay variation were calculated as follows: SE = SD/(√n), n = 5. SE standard error, SD standard deviation, CV coefficient of variation